What's Hot
View all perspectives
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 Ab#1942. RABBIT: Non-melanomatous skin ca on DMARD
Multivariable analysis:
👉Adjusted HR for Abatacept HR ~2
Risk of co-medication with MTX needs further investigation
https://t.co/JOKNyYVZfX @Rheumnow https://t.co/DyG5hbOc8Z
Janet Pope Janetbirdope
3 years 1 month ago
#Abatacept gives more skin cancers in #RheumatoidArthritis from RABBIT registry? pts in Abatacept had more comorbidity? Channeling bias. Who knows. Abst#1942 #ACR21 @RheumNow
Aurelie Najm AurelieRheumo
3 years 1 month ago
Wanna know more about the relation between 🌦🌩 and RA disease activity?
It's below 👇🏻
https://t.co/oUC7lrTEwF
#Abst1912 #ACR21 @RheumNow https://t.co/3iJra047gC
Aurelie Najm AurelieRheumo
3 years 1 month ago
COREVITAS registry 600+ PsA/SpA pts 7yrs follow-up TNFi
❗️Overall low persistency 39% at 2 yrs
❕TNFi persistency = across 6 disease domains
❗️Shorter treatment duration if Enthesitis or Ax PsA
#ACR21 #Abst1818 @RheumNow https://t.co/1aE8eWn4TD
Pedro Castillo _Castillo_Pedro
3 years 1 month ago
NOR-DRUM B: infliximab therapeutic drug monitoring (TDM) vs standard of care (SoC)
Goal inflix. level 3.0-8.0mg/L
🔹axSpA, PsA, PsO, RA, UC, Crohns
🔹Dose⬆️or⬇️based on how level & +/- inflix-Ab
🔹Proactive TDM superior
https://t.co/BHQwJSVHxD
#ACR21 Abst#1946 @RheumNow #ACRBest
David Liew drdavidliew
3 years 1 month ago
Oh, also VTEs. Not designed to do this, but:
- We don't use 10mg bid & we shouldn't start
- 5mg bid looks just fine
- In fact, in patients with a VTE history, 5mg bid is numerically similar (?better) to TNFi
Somehow, VTE in tofa is an overshadowed non-event!
#ACR21 @RheumNow https://t.co/fvMSg49kk6
David Liew drdavidliew
3 years 1 month ago
So today the full NOR-DRUM B details - the first positive RCT for TNFi TDM in rheum
HR 2.09 for worsening with standard care (clinician discretion) vs proactive TDM (change before clinical issue)
Open label, but this is a lot better than guessing!
#ACR21 ABST1946 @RheumNow https://t.co/kyKh00ARVW https://t.co/uW6vYHLI7Y
Aurelie Najm AurelieRheumo
3 years 1 month ago
Different drugs may target different pathways in PsA!
S-cell proteomic biomarkers in SELECT-1 PsA study:
💥UPA targets ▶️ Adaptive immunity, bone metabolism pathways
💥ADA targets ▶️ innate immunity pathways.
Paving the ground for personalised therapy?
#ACR21 #Abst1816 @RheumNow https://t.co/hyMP4PtUnM
sheila RHEUMarampa
3 years 1 month ago
An artificial neural network for detection of radiographic #sacroiliitis in axSpA? @DrPoddubnyy
📌Specificity - 93.9%
📌Sensitivity - 78.7%
Potential tool for interpreting SIJ in nonspecialized ctrs or clinical trials
This is a game changer!🤓
@RheumNow #ACR21 #ACRBest abs1919 https://t.co/2li0dNWtLc
Aurelie Najm AurelieRheumo
3 years 1 month ago
And it’s a wrap!! Time for a pool game🎱 Delighted to have been reporting for @RheumNow alongside an amazing faculty! and delighted to have been able to be around amazing colleagues to attend #ACR21 convergence! See you all next year, hopefully for real! 🤞🏼 https://t.co/JBoKd7zNvl
Akhil Sood MD AkhilSoodMD
3 years 1 month ago
Abstr 1677
Miwa & colleagues studied the effect of bDMARDs on cholesterol levels in RA patients
- bDMARDs may affect HDL levels
- no significant effect was seen on LDL
#ACR21 @RheumNow https://t.co/yb35HMDlxN
Dr. John Cush RheumNow
3 years 1 month ago
Bridging the gap in the delayed diagnosis of axSpA
Dr. Swetha Ann Alexander ( @swethaann23 ) shares the findings from several abstracts presented at #ACR21.
https://t.co/8eEXIbyopA https://t.co/brtaZztRhl
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
3 years 1 month ago
Increased Risk of MACE in Lupus After Noncardiac Surgery: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #0128 presented at #ACR21 annual meeting.
https://t.co/HOVLrhBbuu https://t.co/MAItCSHMIb
Poster Hall